University of Dublin, Trinity College — Publications

Trained Immunity Causes Myeloid Cell Hypercoagulability

Preprint

Venous thromboembolism is common in individuals with chronic inflammatory diseases, but the pathogenic basis for this increased thrombotic risk remains poorly understood. Myeloid cell ‘trained immunity’ describes persistent innate immune cell memory arising from prior exposure to an inflammatory stimulus, leading to an enhanced immune response to subsequent unrelated stimuli. We identify enhanced myeloid cell prothrombotic activity as a novel maladaptive consequence of trained immunity. LPS stimulation of murine bone marrow-derived macrophages trained previously with either β-glucan or free haem exhibited significantly enhanced procoagulant and antifibrinolytic gene expression and activity compared to macrophages stimulated with LPS alone. The β-glucan training-mediated increase in activated myeloid cell procoagulant activity was mediated by enhanced acid sphingomyelinase-mediated tissue factor (TF) functional decryption. Furthermore, pre-treatment with methyltransferase and acetyltransferase inhibitors to erase epigenetic marks associated with innate immune memory diminished trained macrophage TF gene expression in β-glucan-trained macrophages. Functional analysis of splenic monocytes isolated from β-glucan-trained mice revealed enhanced procoagulant activity up to 4 weeks after β-glucan administration compared to monocytes from control mice over the same time period. Remarkably, monocyte procoagulant activity increased proportionately with time since β-glucan administration, before plateauing at 4 weeks. Furthermore, haematopoietic progenitor cells and bone marrow interstitial fluid isolated from β-glucan-trained mice possessed enhanced procoagulant activity compared to control mice. Trained immunity and associated metabolic perturbations may therefore represent novel therapeutic vulnerabilities in immunothrombotic disease development, opening new avenues for targeted intervention.

Aisling M. Rehill, Seán McCluskey, Anna E. Ledwith et al. 2024

Publications

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

生命とは何か : それからの50年 : 未来の生命科学への指針

GSTO1-1 plays a pro-inflammatory role in models of inflammation, colitis and obesity

An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation

“Transflammation”: When Innate Immunity Meets Induced Pluripotency

A gene for Crohn's disease is given the nod

Inhibition of NFkappaB activity by oxidative processes in intact cells — mechanism of action of pyrolidine dithiocarbamate and diamide

Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κB Activation by Toll-like Receptor 4

2014 Editorial Board

High Fat Diet-Induced Obesity Promotes Steroid-Resistant Asthma Through An Nlrp3 Inflammasome-Dependent Mechanism

IL-3

γIP-10

A call for cord blood

Hyaluronic Acid Fragments Activate NFκB in ECV304 Cells Via Its Principal Cell Surface Receptor CD44

Trained Immunity Causes Myeloid Cell Hypercoagulability

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

Author Correction: Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase

Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4+ T Cell Pathogenicity and Suppresses Autoimmunity

Guest Editor

Ras, Protein Kinase Cζ, and IκB Kinases 1 and 2 Are Downstream Effectors of CD44 During the Activation of NF-κB by Hyaluronic Acid Fragments in T-24 Carcinoma Cells